Nearly half a million people are diagnosed and treated for Lyme disease in the U.S. every year, and Pennsylvania is a hot bed ...

ROANOKE, Va. (WDBJ) - Pfizer said it plans to seek regulatory approval of a new vaccine for Lyme disease. Vaccines for Lyme ...

Pfizer (PFE) is preparing to shut a research site and an office location in South San Francisco at the end of April, signaling a notable pullback from the Bay Area’s flagship biotech space, the San ...

Lyme disease is an illness caused by bacteria most commonly spread to humans from ticks. It can cause arthritis, muscle ...

There hasn't been an approved Lyme disease vaccine for more than 20 years, after GSK pulled its shot because of a lack of ...

Pfizer went from Bay Area player to dropout. Now its remaining local employees won't have an office to call home.

Pfizer is behind Eli Lilly and Novo Nordisk in the GLP-1 race, but long-term investors shouldn't count the company out.

Good news has been scarce for this beaten-down drugmaker.

Pfizer and Valneva have blamed “fewer than anticipated” Lyme disease cases for the failure of their phase 3 trial to hit its ...

The drugmaker is seeking regulatory review for the first new shot to combat the disease in decades.

Up until recently, the stock has been a chronic underperformer.

The vaccine could represent a weapon for preventing Lyme, a bacterial infection carried by ticks that is diagnosed and ...